We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NABL:NYSEN-able, Inc. Analysis

Data as of 2026-04-19 - not real-time

$5.20

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Price action: NABL trades at $5.20, well below its 20‑day SMA of $4.77 and 50‑day SMA of $4.88, yet still under the 200‑day SMA of $6.96, indicating a short‑term bearish bias but long‑term downtrend. Technical momentum shows a bullish MACD histogram (+0.08) and an RSI of 60, suggesting limited upside risk of overbought conditions. Valuation: the DCF fair value of $8.93 implies roughly 33% upside, while the forward PE of 10.6 is far cheaper than the industry average PE of 36.7. Fundamentals: revenue grew 11.8% YoY with an impressive 80% gross margin, but operating margin is negative (-1.5%) and trailing EPS remains -$0.09, highlighting earnings pressure. Liquidity: volume is decreasing and average volume exceeds recent trading, flagging modest liquidity concerns.
Catalysts: recent expansion of the Technology Alliance Program (adding Zensec and Atomatik) and a high‑profile partnership with Manchester City bolster the growth narrative and could accelerate adoption of NABL’s security and remote‑management platform. However, analyst sentiment is mixed, with a recent downgrade to Underperform and a “buy” consensus from five analysts. Overall, the stock sits at a valuation discount with upside potential, but execution risk remains elevated.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMAs indicating bearish bias
  • Bullish MACD histogram and RSI near 60 limiting downside
  • Recent partnership announcements providing short‑term sentiment lift

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF‑derived upside of ~33% and forward PE well below industry average
  • Revenue growth and high gross margin supporting earnings recovery
  • Strategic alliance expansions expanding addressable market

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Undervalued relative to intrinsic value but current operating losses
  • Strong cash generation (operating cash flow $93M) and free cash flow
  • Execution risk tied to turning profitability and scaling partnerships

Key Metrics & Analysis

Financial Health

Revenue Growth11.80%
Profit Margin-3.33%
P/E Ratio10.6
ROE-2.18%
ROA1.77%
Debt/Equity53.48
P/B Ratio1.2
Op. Cash Flow$93.2M
Free Cash Flow$90.2M
Industry P/E36.7

Technical Analysis

TrendBearish
RSI59.9
Support$4.14
Resistance$5.25
MA 20$4.77
MA 50$4.88
MA 200$6.96
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21

Valuation

Fair Value$8.93
Target Price$6.95
Upside/Downside33.65%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.06
Volatility50.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.